"The new facility will be outfitted to handle solids manufacturing,” Todd R. Daviau, Ph.D., president and CEO of CoreRx told Outsourcing-Pharma.com. “Initially, it will be set up for granulation, blending, encapsulation, coating and packaging… Additional capabilities will be added as our clients’ needs dictate.”
The new site will add about 40,000 square feet of additional manufacturing and office space and will contain three suites dedicated to process development and clinical production, to make investigational drugs to support clinical trials. Construction will begin in May and is expected to be complete by the middle of Q4 2013.
“We are partnering with one of our clients who has a product approaching Phase 3 with a strong commercial partner showing interest,” Daviau said, noting that more information on the partnerships will be available “in the next few weeks.”
The decision to expand the site is based on uptick in the market for such outsourced manufacturing and the development of niche drugs.
Market data “is showing a trend in this direction” toward clinical trial and commercial manufacturing, and one of CoreRx’s clients “has expressed a need,” Daviau said. He added that the expanded site will help the company maintain its focus on “niche commercial products.”
Construction of the current manufacturing site was completed last July and the initial success of CoreRx and the increasing abundance of biotechnology knowledge, education and training, as well as the inception of the USF College of Pharmacy, has driven the growth in the Tampa area, the company said in a statement.
“This initiative is designed to accelerate the development of new medicines through the closer alignment of our research and development, and manufacturing,” Brian R. McMillan, VP of product development added in a statement.